Exploring CAR T-Cell Therapy During the COVID-19 Pandemic: Mitigation and Management of Adverse Events
This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor T cells. Join us Tuesday, May 26, 2020 at 8 PM EST.
Date/Time: Tuesday, May 26, 2020 at 8 PM EST
This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T cells. We will feature a panel of leading experts to discuss important topics and considerations surrounding CAR T-cell therapies and the patient populations impacted during this time.
Click here to register today!
Topics:
- Review of data on adverse events and strategies for management
- The CAR T cell experience and vein-to-vein time
- Real-world experience using bridging therapy in the setting of new drug approvals and pending approvals
Faculty:
Loretta J. Nastoupil, MD, Associate Professor; Section Chief, Indolent Lymphoma; Section Chef, New Drug Development, Department Lymphoma/Myeloma, UT MD Anderson Cancer Center
Ahmed Galal, MD, FRACP, MSc, Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Duke School of Medicine
Matthew Lunning, DO, Associate Professor, Internal Medicine; Medical Director, Lymphoma Research, Division of Oncology & Hematology, University of Nebraska Medical Center
Sponsored By:
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
